Abstract
Autosomal dominant polycystic kidney disease (ADPKD) is an important cause of ESRD for which there exists no approved therapy in the United States. Defective glucose metabolism has been identified as a feature of ADPKD, and inhibition of glycolysis using glucose analogs ameliorates aggressive PKD in preclinical models. Here, we investigated the effects of chronic treatment with low doses of the glucose analog 2-deoxy-D-glucose (2DG) on ADPKD progression in orthologous and slowly progressive murine models created by inducible inactivation of the Pkd1 gene postnatally. As previously reported, early inactivation (postnatal days 11 and 12) of Pkd1 resulted in PKD developing within weeks, whereas late inactivation (postnatal days 25-28) resulted in PKD developing in months. Irrespective of the timing of Pkd1 gene inactivation, cystic kidneys showed enhanced uptake of 13C-glucose and conversion to 13C-lactate. Administration of 2DG restored normal renal levels of the phosphorylated forms of AMP- Activated protein kinase and its target acetyl-CoA carboxylase. Furthermore, 2DG greatly retarded disease progression in bothmodel systems, reducing the increase in total kidney volume and cystic index and markedly reducing CD45-positive cell infiltration. Notably, chronic administration of low doses (100 mg/kg 5 days per week) of 2DG did not result in any obvious sign of toxicity as assessed by analysis of brain and heart histology as well as behavioral tests. Our data provide proof of principle support for the use of 2DG as a therapeutic strategy in ADPKD.
| Original language | English |
|---|---|
| Pages (from-to) | 1958-1969 |
| Number of pages | 12 |
| Journal | Journal of the American Society of Nephrology |
| Volume | 27 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - 2016 |
Fingerprint
ASJC Scopus subject areas
- Nephrology
Cite this
2-Deoxy-D-glucose ameliorates PKD progression. / Chiaravalli, Marco; Rowe, Isaline Severine Marie-Josephe; Mannella, Valeria; Quilici, Giacomo; Canu, Tamara; Bianchi, Veronica; Gurgone, Antonia; Antunes, Sofia; D'Adamo, Patrizia; Esposito, Antonio; Musco, Giovanna; Boletta, Alessandra.
In: Journal of the American Society of Nephrology, Vol. 27, No. 7, 2016, p. 1958-1969.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - 2-Deoxy-D-glucose ameliorates PKD progression
AU - Chiaravalli, Marco
AU - Rowe, Isaline Severine Marie-Josephe
AU - Mannella, Valeria
AU - Quilici, Giacomo
AU - Canu, Tamara
AU - Bianchi, Veronica
AU - Gurgone, Antonia
AU - Antunes, Sofia
AU - D'Adamo, Patrizia
AU - Esposito, Antonio
AU - Musco, Giovanna
AU - Boletta, Alessandra
PY - 2016
Y1 - 2016
N2 - Autosomal dominant polycystic kidney disease (ADPKD) is an important cause of ESRD for which there exists no approved therapy in the United States. Defective glucose metabolism has been identified as a feature of ADPKD, and inhibition of glycolysis using glucose analogs ameliorates aggressive PKD in preclinical models. Here, we investigated the effects of chronic treatment with low doses of the glucose analog 2-deoxy-D-glucose (2DG) on ADPKD progression in orthologous and slowly progressive murine models created by inducible inactivation of the Pkd1 gene postnatally. As previously reported, early inactivation (postnatal days 11 and 12) of Pkd1 resulted in PKD developing within weeks, whereas late inactivation (postnatal days 25-28) resulted in PKD developing in months. Irrespective of the timing of Pkd1 gene inactivation, cystic kidneys showed enhanced uptake of 13C-glucose and conversion to 13C-lactate. Administration of 2DG restored normal renal levels of the phosphorylated forms of AMP- Activated protein kinase and its target acetyl-CoA carboxylase. Furthermore, 2DG greatly retarded disease progression in bothmodel systems, reducing the increase in total kidney volume and cystic index and markedly reducing CD45-positive cell infiltration. Notably, chronic administration of low doses (100 mg/kg 5 days per week) of 2DG did not result in any obvious sign of toxicity as assessed by analysis of brain and heart histology as well as behavioral tests. Our data provide proof of principle support for the use of 2DG as a therapeutic strategy in ADPKD.
AB - Autosomal dominant polycystic kidney disease (ADPKD) is an important cause of ESRD for which there exists no approved therapy in the United States. Defective glucose metabolism has been identified as a feature of ADPKD, and inhibition of glycolysis using glucose analogs ameliorates aggressive PKD in preclinical models. Here, we investigated the effects of chronic treatment with low doses of the glucose analog 2-deoxy-D-glucose (2DG) on ADPKD progression in orthologous and slowly progressive murine models created by inducible inactivation of the Pkd1 gene postnatally. As previously reported, early inactivation (postnatal days 11 and 12) of Pkd1 resulted in PKD developing within weeks, whereas late inactivation (postnatal days 25-28) resulted in PKD developing in months. Irrespective of the timing of Pkd1 gene inactivation, cystic kidneys showed enhanced uptake of 13C-glucose and conversion to 13C-lactate. Administration of 2DG restored normal renal levels of the phosphorylated forms of AMP- Activated protein kinase and its target acetyl-CoA carboxylase. Furthermore, 2DG greatly retarded disease progression in bothmodel systems, reducing the increase in total kidney volume and cystic index and markedly reducing CD45-positive cell infiltration. Notably, chronic administration of low doses (100 mg/kg 5 days per week) of 2DG did not result in any obvious sign of toxicity as assessed by analysis of brain and heart histology as well as behavioral tests. Our data provide proof of principle support for the use of 2DG as a therapeutic strategy in ADPKD.
UR - http://www.scopus.com/inward/record.url?scp=84978472285&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84978472285&partnerID=8YFLogxK
U2 - 10.1681/ASN.2015030231
DO - 10.1681/ASN.2015030231
M3 - Article
AN - SCOPUS:84978472285
VL - 27
SP - 1958
EP - 1969
JO - Journal of the American Society of Nephrology : JASN
JF - Journal of the American Society of Nephrology : JASN
SN - 1046-6673
IS - 7
ER -